HCM Latest Press Releases

-- October 28, 2026 --

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia Globe Newswire 8:00 PM

-- October 26, 2026 --

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer Globe Newswire 8:00 PM

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 Globe Newswire 4:30 AM

-- October 25, 2026 --

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine Globe Newswire 8:00 PM

-- October 20, 2026 --

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China Globe Newswire 8:00 PM

-- September 28, 2026 --

HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET-Driven EGFR-Mutated Lung Cancer Globe Newswire 8:00 PM

-- September 27, 2026 --

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors Globe Newswire 8:00 PM

-- September 23, 2026 --

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 Globe Newswire 8:00 PM

-- September 3, 2026 --

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy Globe Newswire 12:00 AM

-- August 30, 2026 --

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS Plus TAGRISSO in Treatment-Nave Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China Globe Newswire 8:00 PM

-- August 27, 2026 --

HUTCHMED Announces NMPA Approval for ATLED (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma Globe Newswire 8:00 PM

-- August 16, 2026 --

HUTCHMED Announces ORPATHYS Plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO Globe Newswire 8:00 PM

-- July 30, 2026 --

HUTCHMED Reports 2026 Interim Results Globe Newswire 7:00 AM

-- July 2, 2026 --

HUTCHMED Announces NMPA Approval for ORPATHYS for the treatment of Gastric Cancer Patients with MET Amplification Globe Newswire 4:30 AM

-- June 30, 2026 --

HUTCHMED to Announce 2026 Half-Year Financial Results Globe Newswire 4:30 AM

-- June 24, 2026 --

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026 Globe Newswire 8:00 PM

-- June 11, 2026 --

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress Globe Newswire 8:00 PM

Market Data Delayed 15 Minutes